Table 1.
Clinical characteristics of 7 patients with leukemic follicular lymphoma
| Case | Age | Sex | Race | Stage | Tumors or LAD? |
Lymphocyte count (cells/mm3) |
Therapy | Survival (months) |
Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | M | White | IVB | Yes | 36,600 | R-bendamustine×1 R-cyclophosphamide×5 Maintenance R |
20 | AWD |
| 2 | 60 | M | White | IVB | Yes | 226,950 | R-CVP×6 R-fludarabine×6 R-bendamustine×9 |
33 | Dead |
| 3 | 56 | M | Hispanic | IVB | Yes | 5,000 | R-CHOP×6 R-ICE R-GEMOX |
17 | Dead |
| 4 | 76 | M | Hispanic | IVB | Yes | 11,430 | R-CHOP | 3 | Dead |
| 5 | 40 | M | Hispanic | IVB | Yes | 51,840 | R-CHOP R-ICE R-ESHAP |
15 | AWD |
| 6 | 61 | M | White | IVB | No | 200,000 | R-CHOP ASCT |
34 | AWOD |
| 7 | 64 | M | Hispanic | IVA | Yes | 37,000 | R-CHOP | 4 | AWD |
M: male; LAD: lymphadenopathy; CVP: cyclophosphamide, vincristine, prednisone; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; ICE: ifosfamide, carboplatin, etoposide; GEMOX: gemcitabine, oxaliplatin; ESHAP: etoposide, methylprednisolone, cytarabine, cisplatin; ASCT: autologous stem cell transplant; AWD: alive with disease; AWOD: alive without evidence of disease